6okq
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of the SF12 Fab== | |
| + | <StructureSection load='6okq' size='340' side='right'caption='[[6okq]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6okq]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OKQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6OKQ FirstGlance]. <br> | ||
| + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6okq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6okq OCA], [http://pdbe.org/6okq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6okq RCSB], [http://www.ebi.ac.uk/pdbsum/6okq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6okq ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3A cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448gp120 glycan. Effective bNAbs can therefore be raised against HIV-1 Env's silent face, suggesting their potential for HIV-1 prevention, therapy, and vaccine development. | ||
| - | + | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.,Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ Immunity. 2019 May 14. pii: S1074-7613(19)30194-3. doi:, 10.1016/j.immuni.2019.04.014. PMID:31126879<ref>PMID:31126879</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Barnes, C | + | <div class="pdbe-citations 6okq" style="background-color:#fffaf0;"></div> |
| - | [[Category: Bjorkman, P | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Barnes, C O]] | ||
| + | [[Category: Bjorkman, P J]] | ||
| + | [[Category: Envelope]] | ||
| + | [[Category: Fab structure]] | ||
| + | [[Category: Hiv-1 broadly-neutralizing antibody]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Silent face]] | ||
Revision as of 22:52, 5 June 2019
Crystal structure of the SF12 Fab
| |||||||||||
